Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy. Here, we report a case of advanced NSCLC in a patient wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiratori, Toshihiro, Tanaka, Hisashi, Tabe, Chiori, Tsuchiya, Junichiro, Ishioka, Yoshiko, Itoga, Masamichi, Taima, Kageaki, Takanashi, Shingo, Tasaka, Sadatomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262881/
https://www.ncbi.nlm.nih.gov/pubmed/32285615
http://dx.doi.org/10.1111/1759-7714.13437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262881/
https://www.ncbi.nlm.nih.gov/pubmed/32285615
http://dx.doi.org/10.1111/1759-7714.13437

Ejemplares similares